Novo Nordisk
NVO
Market cap $302B

68.03 USD

-0.17

0.25%

Updated May 22, 12:49 PM EDT

1 day

-0.25%

5 days

5.64%

1 month

13.55%

3 months

-24.90%

6 months

-35.25%

Year to date

-22.27%

1 year

-49.24%

5 years

109.84%

10 years

136.46%

About: With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Employees: 77,406

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,245 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

13% more repeat investments, than reductions

Existing positions increased: 614 | Existing positions reduced: 541

0.42% less ownership

Funds ownership: 9.94% [Q4 2024] → 9.52% (-0.42%) [Q1 2025]

9% less funds holding

Funds holding: 1,637 [Q4 2024] → 1,491 (-146) [Q1 2025]

23% less funds holding in top 10

Funds holding in top 10: 31 [Q4 2024] → 24 (-7) [Q1 2025]

24% less capital invested

Capital invested by funds: $30.1B [Q4 2024] → $23B (-$7.1B) [Q1 2025]

26% less call options, than puts

Call options by funds: $987M | Put options by funds: $1.34B

43% less first-time investments, than exits

New positions opened: 139 | Existing positions closed: 242

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$64

6%

downside

Avg. target

$64

6%

downside

High target

$64

6%

downside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

BMO Capital

Evan David Seigerman

6%downside

$64

Market Perform

Downgraded

17 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 165 articles about NVO published over the past 30 days

24/7 Wall Street

3 Overlooked Dividend Growers With 10%+ Annual Dividend Increases

These dividend stocks can significantly amplify the compounding of your portfolio.

3 Overlooked Dividend Growers With 10%+ Annual Dividend Increases

Novo Nordisk offers Wegovy for $199 for first month to new cash-paying customers

Novo Nordisk said on Thursday it is offering self-paying patients who are new to its weight loss drug Wegovy their first month of medicine for $199 through June 30.

Novo Nordisk offers Wegovy for $199 for first month to new cash-paying customers

New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect

With all doses of FDA-approved Wegovy® fully available nationwide, it is illegal under US compounding laws to make or sell knockoff "semaglutide" drugs, with rare exceptions New, one-time $199 first-month offer for Wegovy® available through June 30, 2025; offer designed to help new self-paying patients previously prescribed unapproved "semaglutide" start on FDA-approved Wegovy® "Choose the Real Thing" campaign launching to raise awareness about the dangers of knockoff "semaglutide" Novo Nordisk intensifies legal actions aimed at protecting patients from risks and dangers associated with compounded "semaglutide" drugs and their foreign illicit active ingredients PLAINSBORO, N.J. , May 22, 2025 /PRNewswire/ -- Today, as the US Food and Drug Administration (FDA) grace period for mass compounding of "semaglutide" expires, Novo Nordisk announced a series of initiatives to further support patient access to authentic, FDA-approved Wegovy® (semaglutide) injection 2.4 mg.

New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect

Focus: Novo Nordisk's former chief makes comeback to steer choice of new CEO

Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press conference in Copenhagen: "You ain't seen nothing yet."

Focus: Novo Nordisk's former chief makes comeback to steer choice of new CEO

Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs

Cigna's Evernorth unit said a new coverage deal with Eli Lilly and Novo Nordisk will bring lower copays for insured patients The company hopes the new discount, which caps monthly out-of-pocket costs at $200 for Wegovy and Zepbound, will convince more employers to offer coverage of the drugs.

Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs

Novo Nordisk Foundation pledges $57 million to WHO amid US funding gap

The Novo Nordisk Foundation has pledged up to DKK 380 million ($57.76 million) to the World Health Organization (WHO) to expand its tie-up with the United Nations agency for another four years, the philanthropic body said on Wednesday.

Novo Nordisk Foundation pledges $57 million to WHO amid US funding gap

The Motley Fool

Best Healthcare Stocks: Eli Lilly vs. Novo Nordisk

Eli Lilly (LLY -1.25%) and Novo Nordisk (NVO 1.72%) are pitted against each other, but only one can be my preferred healthcare stock.

Best Healthcare Stocks: Eli Lilly vs. Novo Nordisk

Forget About Dividend Yield, Do This Instead

Focus on dividend sustainability and business quality, not just high yield, to build reliable passive income. Avoid overexposure to cyclical sectors; prioritize companies with resilient dividends through recessions, like consumer staples and pharma. Dividend growth and low payout ratios are key for long-term compounding; patience is essential for meaningful yield on cost.

Forget About Dividend Yield, Do This Instead

24/7 Wall Street

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (May 2025)

Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (May 2025)

The Motley Fool

Why Novo Nordisk Stock Popped on Tuesday

Novo Nordisk (NVO 1.98%) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market.

Why Novo Nordisk Stock Popped on Tuesday

See News Rankings

Charts implemented using Lightweight Charts™